课题基金 / 基金详情

Mechanisms of tumor suppression by the chromatin deacetylase SIRT6

Mechanisms of tumor suppression by the chromatin deacetylase SIRT6
染色质脱乙酰酶 SIRT6 抑制肿瘤的机制
批准号:
8689985
负责人:
David Benner Lombard
金额:
$16.17万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-07-01 至 2015-06-30

项目摘要

项目成果

David Benner Lombard的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):染色体稳定性丧失是人类癌症的常见特征。细胞如何维持染色体完整性还不完全清楚,但很明显,许多途径和蛋白质复合物参与其中。保持正确的染色体含量(整倍性)是整体染色体稳定性的重要因素。新兴的数据表明,着丝粒周围重复DNA元件的表观遗传沉默在整倍性的维持中起着关键作用。有缺陷的着丝粒周围沉默足以诱导染色体不稳定性,并且在动物模型中诱导恶性肿瘤。本申请关注sirtuin SIRT6在肿瘤抑制、近着丝粒沉默和倍性维持中的新功能。sirtuins是一个蛋白质脱乙酰酶家族,促进哺乳动物健康的许多方面,其中包括肿瘤抑制。该实验室的长期目标是阐明sirtuins,特别是SIRT 6促进健康的机制。申请人的实验室最近发表的工作表明,SIRT6在人和小鼠中起肠道肿瘤抑制剂的作用,至少部分地通过减弱MYC和HIF 1信号传导。本申请的目的是阐明SIRT6在肿瘤抑制中的第三种作用,特别是在着丝粒周围沉默和染色体稳定性中。本申请的中心假设是SIRT6促进近着丝粒DNA的表观遗传沉默以促进整倍性维持,这是一种有助于其肿瘤抑制功能的功能。这些研究的基本原理是,SIRT6,近着丝粒沉默和整倍性之间的关系的机制解剖将有助于提高对染色体稳定性的整体理解。这项工作将在三个具体目标下进行。首先,将阐明SIRT6与已知染色质沉默因子相互作用的意义。SIRT6缺陷细胞中的潜在有丝分裂缺陷将B活细胞成像来鉴定。其次,将在肠上皮细胞和腺瘤中评估SIRT6功能丧失对恶性性质和非整倍体诱导的影响。第三,将在体内测试SIRT6过表达抑制腺瘤病的能力。该方法是创新的,因为近着丝粒沉默对倍性维持的贡献仍然不完全清楚,SIRT6以前没有与该过程相关。这项工作意义重大,因为它可能为倍性维持机制提供新的见解,而倍性维持机制又是整体基因组稳定性和肿瘤抑制的主要因素。
英文摘要
DESCRIPTION (provided by applicant): Loss of chromosomal stability is a common feature of human carcinomas. How cells maintain chromosomal integrity is incompletely understood; however it is clear that many pathways and protein complexes are involved. Maintenance of the correct chromosomal content (euploidy) is an important contributor to overall chromosomal stability. Emerging data indicate that epigenetic silencing of pericentromeric repetitive DNA elements plays a key role in maintenance of euploidy. Defective pericentromeric silencing is sufficient to induce chromosomal instability and, in animal models, malignancy. This application focuses on novel functions for the sirtuin SIRT6 in tumor suppression, pericentromeric silencing, and ploidy maintenance. The sirtuins are a family of protein deacetylases that promote many aspects of healthspan in mammals, among them tumor suppression. The long- term goal of the laboratory is to elucidate mechanisms by which sirtuins, in particular SIRT6, promote healthspan. Recently published work by the applicant's laboratory has shown that SIRT6 functions as an intestinal tumor suppressor in humans and mice, at least in part via attenuation of MYC and HIF1 signaling. The objective of this application is to elucidate a third role of SIRT6 in tumor suppression, specifically in pericentromeric silencing and chromosomal stability. The central hypothesis of this application is that SIRT6 promotes epigenetic silencing of pericentromeric DNA to promote euploidy maintenance, a function that contributes to its tumor suppressor function. The rationale for these studies is that a mechanistic dissection of the relationships between SIRT6, pericentromeric silencing, and euploidy will contribute to an enhanced understanding of chromosomal stability overall. This work will be carried out in three Specific Aims. First, the significance of SIRT6's interactions with known chromatin silencing factors will be elucidated. Potential mitotic defects in SIRT6-deficient cells will be identified b live-cell imaging. Second, the impact of loss of SIRT6 function will be assessed in intestinal epithelial cells and adenomas with respect to malignant properties and induction of aneuploidy. Third, the ability of SIRT6 overexpression to suppress adenomatosis will be tested in vivo. The approach is innovative, in that the contribution of pericentromeric silencing to ploidy maintenance is still incompletely understood, and SIRT6 has not previously been linked to this process. The work is significant, in that it is likely to provide new insights into mechanisms of ploidy maintenance, which in turn is a major factor in overall genomic stability and tumor suppression.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
SIRT5 inhibitors and degraders as novel treatments for Ewing sarcoma
SIRT5 inhibitors and degraders as novel treatments for Ewing sarcoma
Targeting the longevity regulator PAPP-A with small molecule inhibitors
Targeting the longevity regulator PAPP-A with small molecule inhibitors
海外基金